Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

(2020) Jonathan Rosenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

(2020) Jonathan E. Rosenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.

(2019) Christopher J. Hoimes et al.   JOURNAL OF CLINICAL ONCOLOGY

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

(2019) Jonathan E. Rosenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Erdafitinib for the treatment of metastatic bladder cancer

(2019) Kamaneh Montazeri et al.   Expert Review of Clinical Pharmacology

Immunotherapy Advances in Urothelial Carcinoma

(2018) Rohit K Jain et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

(2016) P. M. Challita-Eid et al.   CANCER RESEARCH

CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer

(2015) Martin Turcotte et al.   CANCER RESEARCH

The Immunoglobulin-Like Cell Adhesion Molecule Nectin and Its Associated Protein Afadin

(2008) Yoshimi Takai et al.   Annual Review of Cell and Developmental Biology